Apigenin/Luteolin-based regenerative therapy for curing Glaucoma: A pharmaceutical mixture encompassing Apigenin and Luteolin increases the expression of genes that promote regeneration,  promotes reprogramming of aged eye cells, increases telomerase expression, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against and reverses glaucoma,  via upregulation of its target gene, 6/December/2019, 5.40 am

Vitamin-E based therapy for pain management: Mechanistic insights into how VitmainE isoform γ-tocotrienol (γT3) functions as an analgesic agent: γ-tocotrienol (γT3) increases the expression of PD-L1, decreases the expression of Cox-2, TRPV1, and CGPR, attenuates acute and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability, via up-regulation of its target gene, 3/November/2019, 9.29 am
December 3, 2019
ROBLOX HACKS FOR FREE ROBUX GENERATOR
December 8, 2019
Show all

Introduction: What they say

A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes Medical Institute, Bar Harbor, ME 04609, USA shows that Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice.” This research paper was published, in the 9 February 2017 issue of the journal “Science” [One of the best research journals in “General Science” with an I.F of 41.063], by     Prof. Simon W. M. John and Pete A. Williams and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Apigenin/Luteolin-based regenerative therapy for curing Glaucoma: A pharmaceutical mixture encompassing Apigenin and Luteolin increases the expression of genes that promote regeneration,  promotes reprogramming of aged eye cells, increases telomerase expression, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against and reverses glaucoma,  via upregulation of its target gene


From the significance of the study to public health relevance:

Given that: (1) Glaucoma is a neurodegenerative disease; (2) more than 80 million people worldwide are affected by Glaucoma; (2) Glaucoma is the second leading cause of blindness; (3) Glucosma has no cure; (4) vision lost due to glaucoma is irreversible; (5) the global economic cost spent for Glaucoma treatment is enormous, there is an urgent need to find: (i) a way to induce regeneration of ganglion cells that were lost in Glaucoma; (ii) a cheaper alternative to the existing expensive anti-glaucoma drugs; (iii) a side-effect-free natural product-based drug; and (v) a way to cure, not just treat, Glaucoma permanently.


What is known?

Prof.Simon’s research team has recently shown that:(1) glaucoma-prone mice suffer from mitochondrial abnormalities, resulting in neuronal dysfunction; (2) NAD+ levels decrease with age; (3) administration of Niacin/Vitamin-B3 protects against glaucoma; (4) expression of Nmnat1, a key NAD+-producing enzyme, protects against glaucoma, suggesting that increasing the expression of Nmnat1 in glaucoma patients may alleviate glaucoma.


From research findings to Therapeutic opportunity:

This study suggests, for the first time, that a pharmaceutical mixture encompassing Apigenin and Luteolin, by increasing the expression of its target genes, it could increase the expression of Nmnat1. Thereby, it could: (1) increase NAD+ levels; (2) increase telomerase expression; (3) increase the expression of genes that promote regeneration; (4) promote reprogramming of aged eye cells; (5) decrease Intraocular pressure; (6) improve pressure-induced damage; (7) increase insulin sensitivity; and (8) alleviate/reverse/cure glaucoma (Fig.1). Thus, Apigenin and Luteolin,  either alone or in combination with other drugs or compounds, can be used to cure or reverse or treat Glaucoma.

Figure 1. Mechanistic insights into how Apigenin attenuates or cures glaucoma. Apigenin, by increasing the expression of its target genes, it increases the expression of genes that promote regeneration and telomerase, enhances NAD+ levels, and attenuates/reverses/cures glaucoma.

Figure 2. Mechanistic insights into how a pharmaceutical mixture encompassing Apigenin and Luteolin attenuates or cures glaucoma. Lithium, by increasing the expression of its target genes,  increases the expression of genes that promote regeneration and telomerase, enhances NAD+ levels, and attenuates/reverses/cures glaucoma.

Figure 3. Flavone Apigenin (also known as Chamomile, Apigenol, Versulin,  4′,5,7-Trihydroxyflavone, and others), derived from Chamomile, Parsley, Celery and others, functions as an anti-glaucoma agent by increasing NAD+ levels

Figure 4. Flavone Luteolin (also known as Luteolol, Digitoflavone, Flacitran, Luteoline, 3′,4′,5,7-Tetrahydroxyflavone), derived from Oregano, Radicchio, Sweet pepper, Millet and others,  functions as an anti-glaucoma agent by increasing NAD+ levels

Figure 5. A pharmaceutical mixture encompassing Apigenin and Luteolin functions as an anti-glaucoma agent by increasing NAD+ levels , and by promoting regeneration of aged eye cells

Figure 6. While it had been shown earlier that Vitamin-B3 prevents glaucoma in aged mice, its mechanism of action remains largely unclear. This study suggests that a pharmaceutical mixture encompassing Apigenin and Luteolin could promote reprogramming of aged eye cells and reverse glaucoma by upregulating the expression of NMNAT1, and telomerase,  increase the levels of NAD+, and genes that promote regeneration.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does a pharmaceutical mixture encompassing Apigenin and Luteolin increase the levels of NMNAT1, telomerase, and NAD+?

Amount: $1, 500#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, L., Apigenin/Luteolin-based regenerative therapy for curing Glaucoma: A pharmaceutical mixture encompassing Apigenin and Luteolin increases the expression of genes that promote regeneration,  promotes reprogramming of aged eye cells, increases telomerase expression, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against and reverses glaucoma,  via upregulation of its target gene, 6/December/2019, 5.40 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Comments are closed.